Trichomoniasis, caused by the protozoan Trichomonas vaginalis, is a common sexually transmitted infection. It affects the urogenital tract, causing inflammation and various symptoms in both men and women. Understanding its pathogenesis is key to effective diagnosis and treatment.
Symptoms vary between sexes, with women often experiencing more noticeable signs. Diagnosis involves microscopy, culture, or molecular tests. Treatment typically includes metronidazole or tinidazole, with partner therapy crucial for preventing reinfection and further transmission.
Protozoan Infections of the Urogenital System
Trichomoniasis pathogenesis and effects
- Trichomonas vaginalis flagellated protozoan parasite causes trichomoniasis transmitted through sexual contact (vaginal, anal, oral sex)
- T. vaginalis adheres to and invades urogenital tract epithelial cells secretes proteases and enzymes damaging cells induces inflammatory response leading to urogenital tract inflammation
- In females, T. vaginalis primarily affects vagina and cervix causes vaginitis with vaginal discharge, itching, irritation may lead to cervicitis and pelvic inflammatory disease (PID) increases risk of HIV acquisition and transmission
- In males, T. vaginalis infects urethra, prostate, epididymis can cause urethritis, prostatitis, epididymitis often asymptomatic or presents with mild symptoms
- Understanding the protozoan life cycle is crucial for effective treatment and prevention strategies
Symptoms and diagnosis of trichomoniasis
- Female symptoms:
- Frothy, yellow-green vaginal discharge with strong odor
- Vaginal itching, burning, irritation
- Dysuria (painful urination) and dyspareunia (painful intercourse)
- Lower abdominal pain and discomfort
- Male symptoms:
- Often asymptomatic or mild symptoms
- Urethral discharge, itching, burning
- Dysuria and urinary frequency
- Diagnostic methods:
- Wet mount microscopy directly visualizes motile trophozoites in vaginal or urethral discharge
- Culture inoculates discharge onto specialized media (Diamond's medium) incubates for 2-7 days
- Nucleic acid amplification tests (NAATs) detect T. vaginalis DNA using PCR or other molecular methods
- Rapid antigen detection tests use immunochromatographic assays to detect T. vaginalis antigens in vaginal or urethral samples
- Proper understanding of urogenital system anatomy is essential for accurate diagnosis and treatment
Treatment options for trichomoniasis
- Metronidazole (Flagyl) first-line treatment for trichomoniasis
- Single-dose oral therapy: 2 g metronidazole
- Alternative regimen: 500 mg metronidazole twice daily for 7 days
- Cure rates 90-95% with single-dose therapy, 95-100% with 7-day regimen
- Tinidazole (Tindamax) alternative to metronidazole
- Single-dose oral therapy: 2 g tinidazole
- Similar efficacy to metronidazole, with cure rates 86-100%
- Partner therapy essential to prevent reinfection and further transmission simultaneously treats all sexual partners, regardless of symptoms using same treatment regimens as infected individual
- Follow-up testing recommended 2-3 months after treatment to detect treatment failure or reinfection
- Metronidazole and tinidazole resistance rare but reported higher doses or longer treatment durations may be necessary for resistant cases combination therapy with other antiprotozoal agents (paromomycin) may be considered
Considerations for Special Populations
- Sexually transmitted infections, including trichomoniasis, require special attention in pregnancy and adolescents
- Immunocompromised patients may experience more severe symptoms and require longer treatment durations
- Antibiotic resistance in T. vaginalis is a growing concern, necessitating ongoing surveillance and research into alternative treatments